Figure 3From: Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma Mean maximum percentage decline in FEV 1 after exercise for each individual subject in study 2. Multiple doses of MEDI-528 resulted in a reduction in the mean maximum percentage decrease in FEV1 after exercise as compared to placebo.Back to article page